A rapid method for determining the presence of barbiturate in serum has been needed for some time. 
Presently
used methods are all relatively time-consuming.
A rapid immunoassay for the detection of barbiturate in urine, the "Enzyme Multiplied Immunoassay Technique" (EMIT), has recently become available. We have compared results of the EMIT urine assay with results of a spectrophotometric assay of serum (203 patients). Our purpose was: (a)
to determine whether a negative result would be obtained with the EMIT assay in cases in which barbiturate was not a factor in coma, and (b) to determine whether a positive EMIT result would be obtained when a significant ( 
volunteers
(2), whose urine/blood ratios for barbiturate indicated that a concentration of 3 ig/ml in blood is accompanied by a concentration in urine of >1 ig/ml. Thus, a rapid general quantitative assay for barbiturates in urine may indicate the need for a more time-consuming, quantitative serum barbiturate assay. The EMIT system meets the required criteria for assay time and accuracy. The balance could represent individuals using short-acting barbiturates, which were partly metabolized before the serum was sampled.
Materials and Methods
In any case, for our purposes these apparent false positives would have resulted in, at most, nine unnecessary serum barbiturate assays, a favorable outcome in the light of the 100 serum assays not required because of the EMIT urine assay. The four cases in which a negative EMIT urine response was obtained with 
